Skip to main content

Pain clinical trials at UCSF
3 in progress, 1 open to new patients

  • Deep Brain Stimulation (DBS) for Chronic Neuropathic Pain

    open to eligible people ages 21 years and up

    This study evaluates invasive deep brain stimulation (DBS) in the treatment of two types of chronic neuropathic pain, i) thalamic pain syndrome and ii) phantom limb pain. Participants will be implanted with recording / stimulation electrodes in pain-related circuits of the brain. Relief of pain symptoms with stimulation will be studied in both groups. It is hypothesized that neural signals will correlate with pain states and that DBS can disrupt these pain states in both groups, perhaps with differences in underlying neural mechanisms for pain relief.

    San Francisco, California

  • Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

    Sorry, currently not accepting new patients, but might later

    This randomized phase III trial studies how well combination chemotherapy works in treating young patients with newly diagnosed B acute lymphoblastic leukemia that is likely to come back or spread, and in patients with Philadelphia chromosome (Ph)-like tyrosine kinase inhibitor (TKI) sensitive mutations. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) and giving the drugs in different doses and in different combinations may kill more cancer cells.

    Oakland, California and other locations

  • Vaporized Cannabis for Chronic Pain Associated With Sickle Cell Disease

    Sorry, in progress, not accepting new patients

    Our primary objective is to assess whether inhaling vaporized cannabis ameliorates chronic pain in patients with sickle cell disease (SCD). As these patients will all be on chronic opioid analgesics, the investigators will also assess the possible synergistic affect between inhaled cannabis and opioids. The investigators will also assess the clinical safety of the concomitant use of cannabinoids and these opioids in patients with SCD by monitoring the short-term side effects associated with combined therapy. Finally, the investigators will evaluate the short-term effects of inhaled cannabis on markers of inflammation and disease progression in patients with SCD. Hypotheses are as follows: 1. Inhaled cannabis will significantly reduce chronic pain in patients with SCD. 2. Inhaled cannabis will significantly alter the short-term side effects experienced by patients who take opioids for SCD. 3. Inhaled cannabis will significantly alter markers of inflammation and disease progression in patients with SCD compared to placebo.

    San Francisco, California